ArticleCardiovascular & hematological disorders drug targets2022
Effect of
Article in Cardiovascular & hematological disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Citronellol Induces Apoptosis via Differential Regulation of Caspase-3, NF-κB, and JAK2 Signaling Pathways in Glioblastoma Cell Line.Food science & nutrition · 2025Article
- Chemical Profiling and Biological Activities ofPlants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsThe study aimed to assess the antihyperglycemic activity of Pelargonium graveolens.
backgroundPelargonium graveolens (P. graveolens) (Geraniaceae) is a medicinal plant frequently used in traditional medicine in Morocco and Algeria as a remedy against a multitude of illnesses. Interestingly, it is also used in the Moroccan pharmacopeia for managing diabetes.
objectiveThe current study was carried out in order to assess the antihyperglycemic activity of P. graveolens in normal and streptozotocin(STZ)-induced diabetic rats, as well as to evaluate the acute toxicity of the aqueous extract of leaves of Pelargonium graveolens (PGLAE).
methodsThe therapeutic effect of PGLAE at a dose of 40 mg/kg on blood glucose levels was investigated in normal and STZ-induced diabetic rats after a single oral (6h) and a repeated (15 days) oral administration. The acute toxicity of the PGLAE was examined in accordance with the OECD test guideline. Post-treatment, body weight, signs of toxicity, and/or mortality were observed for 14 days. Further assays, such as the oral glucose tolerance test, histopathological examination, and antioxidant activity, were also performed according to standard protocols.
resultsFindings exhibited that both single and repeated oral doses of PGLAE (40 mg/kg) caused a significant reduction in blood glucose levels of normal and diabetic rats. All treated animals survived and no apparent adverse effects were observed during the duration of the acute toxicity study. Importantly, oral LD50 of PGLAE was greater than 2000 mg/kg BW. Furthermore, a remarkable influence on glucose tolerance was also noticed after PGLAE treatment. Moreover, PGLAE was able to improve the histopathological structure of the liver and possesses a potential antioxidant effect in vitro.
conclusionIn conclusion, this study reported the antidiabetic effects of PGLAE in rats, supporting its traditional use for the management of diabetes.
Indexed as
Identifiers
35170422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.